Lipids and the kidney
Author(s)
Bibliographic Information
Lipids and the kidney
（Contributions to nephrology, vol. 120）
Karger, 1997
Available at 4 libraries
Note
Includes bibliographical references and index
Description and Table of Contents
Description
During the past decade, experimental and clinical studies have suggested that dyslipidemia may be an important risk factor for the progression of renal disease. This volume explores in great detail recent advances in our understanding of the pathogenesis and treatment of this common complication of progressive renal injury. In the experimental investigations presented, emphasis is placed on specific disturbances of lipids that are seen in progressive renal disease including the effects of oxidatively modified lipoproteins and Lp(a) on various functions of the glomerular cells. Clinical studies have identified dyslipidemia as a risk factor for progressive renal disease in diabetes mellitus, various non-diabetic renal diseases, and most recently in patients with progressive renal allograft loss. An emerging interest in the genetics of dyslipidemia has recently arisen and this topic as it specifically relates to progressive renal disease is discussed. The final section of the book offers new insights into the mechanisms of action of antilipemic therapy used in the treatment of dyslipidemia. This volume should be read by all nephrologists caring for patients with progressive renal disease and by physicians interested in the biology of lipids, diabetes and essential hypertension.
Table of Contents
- Part 1 Lipids as a risk factor for renal disease: lipid abnormalities in progressive renal insufficiency
- hypertension, hyperlipidemia and microalbuminuria
- apolipoprotein E phenotype and renal disease
- lipoprotein glomerulopathy and its pathogenesis
- cholesterol as a predictor of progression in diabetic renal disease
- cholesterol as a predictor of progression in nondiabetic chronic renal disease
- role of lipids in chronic renal allograft rejection. Part 2 Treatment of dyslipidemia in patients with renal disease: effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients
- treatment of hyperlipidemia in patients with non-insulin-dependent diabetes mellitus with progressive nephropathy
- effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease
- the effect of HMG-CoA reductase inhibitors on chronic allograft rejection
- long-term low-density lipoprotein immunoapheresis in renal disease. Part 3 Mechanisms of lipid-induced renal injury - experimental insights: role of lipids in progressive renal disease - insights from the analbuminemic rat
- hyperlipidemia and tissue contents of N-sigma-(carboxymethyl)lysine in streptozotocin diabetes
- effects of lipids on glomerular fibrinolysis in vitro
- effects of lipoprotein (a) on mesangial cell biology
- HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-thy-1.1 nephritis
- the role of oxidatively modified lipoproteins in lipid nephropathy
- effect of low-density lipoproteins on mesangial cell expression of monocyte chemoattractant peptides. Part 4 New insights into effects of antilipemic therapy: regulation of mesangial cell proliferation by the mevalonate pathway
- hypercholesterolemia and progressive kidney disease - the role of macrophages and macrophage-derived products
- central role of the transcription factor nuclear factor-kB in mesangial cell production of chemokines
- isoprenoids, ras and proliferative glomerular disease.
by "Nielsen BookData"